PTC Therapeutics
40°33′03″N 74°25′23″W / 40.550722°N 74.423071°W
 | |
| Company type | Public |
|---|---|
| Nasdaq: PTCT | |
| Industry | Pharmaceuticals |
| Founded | 1 January 1998  |
| Headquarters | , United States |
| Website | ptcbio |
PTC Therapeutics is a pharmaceutical company focused on the development of small molecule, orally administered treatments for orphan diseases.[1] As of September 2013[update], PTC was headquartered at 100 Corporate Court, South Plainfield, New Jersey.[2]: cover
They are the company responsible for the development of Ataluren.[3]
As of September 2009, PTC has entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system disease targets. Roche said use of PTC's GEMS technology for the identification of small molecules "will enable Roche to address important disease mechanisms that were intractable with conventional approaches." [4]
References
- ^ Bhutta, Sunya (December 2013). "Biopharma Blossoming in the Garden State". Biobusiness. Gen. Eng. Biotechnol. News. Vol. 33, no. 21. p. 15.
- ^ "PTC Therapeutics, Inc". edgar archives. 10-Q. USSEC. September 30, 2013. Retrieved January 5, 2014.
- ^ Hamed SA (2006). "Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy". IDrugs : the investigational drugs journal. 9 (11): 783–9. PMID 17096300.
- ^ http://www.firstwordplus.com/Fws.do?articleid=A2B13ACB78294EB0A27EE127D8339BF3
Further reading
- Schneider, Ilene (2009). "Firm Aims to Regulate RNA in Rare Diseases". Genetic Engineering & Biotechnology News. 29 (8): 14. Retrieved 2009-04-25.
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |